Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update

Hookipa Pharma Inc (NASDAQ:HOOK) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 66,200 shares, a decrease of 21.3% from the February 13th total of 84,100 shares. Based on an average daily volume of 122,100 shares, the short-interest ratio is currently 0.5 days. Approximately 1.0% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JMP Securities dropped their target price on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a report on Thursday, November 21st. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $48.00 to $2.00 in a report on Friday, December 20th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Hookipa Pharma in a report on Friday, January 10th.

Hedge Funds Weigh In On Hookipa Pharma

A number of institutional investors have recently bought and sold shares of the stock. Ikarian Capital LLC bought a new position in shares of Hookipa Pharma during the third quarter valued at approximately $228,000. Gilead Sciences Inc. bought a new position in shares of Hookipa Pharma during the fourth quarter valued at approximately $3,771,000. Millennium Management LLC bought a new position in shares of Hookipa Pharma during the fourth quarter valued at approximately $31,000. Finally, Squarepoint Ops LLC bought a new position in shares of Hookipa Pharma during the fourth quarter valued at approximately $104,000. 63.88% of the stock is owned by institutional investors.

Hookipa Pharma Price Performance

HOOK stock traded up $0.02 during trading on Monday, reaching $1.19. The company had a trading volume of 18,340 shares, compared to its average volume of 74,538. Hookipa Pharma has a 52 week low of $1.11 and a 52 week high of $10.50. The company has a market cap of $14.35 million, a P/E ratio of -0.32 and a beta of 0.71. The business has a 50 day moving average of $1.75 and a 200 day moving average of $2.86.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.